04:21 AM EDT, 04/29/2025 (MT Newswires) -- Heron Therapeutics ( HRTX ) said late Monday that it appointed Mark Hensley as its chief operating officer.
Before joining Heron, Hensley held several roles at Veloxis Pharmaceuticals, including chief executive officer from 2021 to 2024, and chief operating officer and chief commercial officer from 2018 to 2021.